Page 128 - 南京医科大学自然版

第46卷第4期
·596 · 南 京 医 科 大 学 学 报 2026年4月

［39］GUIÈZE R，LIU V M，ROSEBROCK D，et al. Mitochon⁃ Glutaminolysis is a metabolic dependency in FLT3 ITD
drial reprogramming underlies resistance to BCL⁃2 inhibi⁃ acute myeloid leukemia unmasked by FLT3 tyrosine ki⁃
tion in lymphoid malignancies［J］. Cancer Cell，2019，36 nase inhibition［J］. Blood，2018，131（15）：1639-1653
（4）：369-384 ［51］KOLBA M D，DUDKA W，ZAREBA⁃KOZIOŁ M，et al.
［40］ZHOU H M，ZHANG J G，ZHANG X，et al. Targeting can⁃ Tunneling nanotube ⁃ mediated intercellular vesicle and
cer stem cells for reversing therapy resistance：mecha⁃ protein transfer in the stroma ⁃ provided imatinib resis⁃
nism，signaling，and prospective agents［J］. Signal Trans⁃ tance in chronic myeloid leukemia cells［J］. Cell Death
duct Target Ther，2021，6（1）：62 Dis，2019，10（11）：817
［41］CHEN C L，UTHAYA KUMAR D B，PUNJ V，et al. ［52］ROCA⁃PORTOLES A，RODRIGUEZ⁃BLANCO G，SUMP⁃
NANOG metabolically reprograms tumor⁃initiating stem⁃ TON D，et al. Venetoclax causes metabolic reprogram⁃
like cells through tumorigenic changes in oxidative phos⁃ ming independent of BCL ⁃ 2 inhibition［J］. Cell Death
phorylation and fatty acid metabolism［J］. Cell Metab， Dis，2020，11（8）：616
2016，23（1）：206-219 ［53］ZHANG Y，ZHANG X，YANG X，et al. EGFR⁃TKIs in⁃
［42］NAIK P P，MUKHOPADHYAY S，PANDA P K，et al. Au⁃ duced DPP4 drives metabolic reprogramming of persister
tophagy regulates cisplatin⁃induced stemness and chemo⁃ cells in lung cancer［J］. Adv Sci（Weinh），2025，12（31）：
resistance via the upregulation of CD44，ABCB1 and e06950
ADAM17 in oral squamous cell carcinoma［J］. Cell Prolif， ［54］WU B，XIONG J，ZHOU Y，et al. Luteolin enhances
2018，51（1）：e12411 TRAIL sensitivity in non ⁃ small cell lung cancer cells
［43］IKEDA K，HORIE⁃INOUE K，SUZUKI T，et al. Mitochon⁃ through increasing DR5 expression and Drp1 ⁃ mediated
drial super complex assembly promotes breast and endo⁃ mitochondrial fission［J］. Arch Biochem Biophys，2020，
metrial tumorigenesis by metabolic alterations and en⁃ 692：108539
hanced hypoxia tolerance［J］. Nat Commun，2019，10（1）： ［55］HE P，FENG J J，XIA X T，et al. Discovery of a potent and
4108 oral available complex I OXPHOS inhibitor that abrogates
［44］GONG Y，JI P，YANG Y S，et al. Metabolic ⁃ pathway ⁃ tumor growth and circumvents MEKi resistance［J］. J
based subtyping of triple ⁃ negative breast cancer reveals Med Chem，2023，66（9）：6047-6069
potential therapeutic targets［J］. Cell Metab，2021，33 ［56］XIN Q，JI Q H，ZHANG Y，et al. Aberrant ROS served as
（1）：51-64 an acquired vulnerability of cisplatin⁃resistant lung can⁃
［45］LUO M，FU A F，WU R F，et al. High expression of G6PD cer［J］. Oxid Med Cell Longev，2022，2022：1112987
increases doxorubicin resistance in triple negative breast ［57］XIA W J，QI X，LI M F，et al. Metformin promotes antican⁃
cancer cells by maintaining GSH level［J］. Int J Biol Sci， cer activity of NK cells in a p38 MAPK dependent man⁃
2022，18（3）：1120-1133 ner［J］. Oncoimmunology，2021，10（1）：1995999
［46］WINTER M，NAIT ELDJOUDI A，GUETTE C，et al. Mito⁃ ［58］FUHR V，HEIDENREICH S，SRIVASTAVA M，et al.
chondrial adaptation decreases drug sensitivity of persis⁃ CD52 and OXPHOS⁃potential targets in ibrutinib⁃treated
tent triple negative breast cancer cells surviving combina⁃ mantle cell lymphoma［J］. Cell Death Discov，2022，8
tory and sequential chemotherapy［J］. Neoplasia，2023， （1）：505
46：100949 ［59］BARAN N，LODI A，DHUNGANA Y，et al. Inhibition of
［47］EVANS K W，YUCA E K，SCOTT S S，et al. Oxidative mitochondrial complex Ⅰ reverses NOTCH1⁃driven meta⁃
phosphorylation is a metabolic vulnerability in chemothe⁃ bolic reprogramming in T⁃cell acute lymphoblastic leuke⁃
rapy ⁃ resistant triple ⁃ negative breast cancer［J］. Cancer mia［J］. Nat Commun，2022，13（1）：2801
Res，2021，81（21）：5572-5581 ［60］CHEN D W，BARSOUMIAN H B，FISCHER G，et al.
［48］ABRAHAM A，QIU S W，CHACKO B K，et al. SIRT1 regu⁃ Combination treatment with radiotherapy and a novel oxi⁃
lates metabolism and leukemogenic potential in CML dative phosphorylation inhibitor overcomes PD ⁃ 1 resis⁃
stem cells［J］. J Clin Invest，2019，129（7）：2685-2701 tance and enhances antitumor immunity［J］. J Immunother
［49］FORTE D，GARCÍA⁃FERNÁNDEZ M，SÁNCHEZ⁃AGU⁃ Cancer，2020，8（1）：e000289
ILERA A，et al. Bone marrow mesenchymal stem cells ［61］VITIELLO G A，MEDINA B D，ZENG S，et al. Mitochon⁃
support acute myeloid leukemia bioenergetics and enhance drial inhibition augments the efficacy of imatinib by reset⁃
antioxidant defense and escape from chemotherapy［J］. ting the metabolic phenotype of gastrointestinal stromal tu⁃
Cell Metab，2020，32（5）：829-843 mor［J］. Clin Cancer Res，2018，24（4）：972-984
［50］GALLIPOLI P，GIOTOPOULOS G，TZELEPIS K，et al. ［62］GIARRIZZO M ，LACOMB J F ，PATEL H R ，et al.